Monitor for the CNTY-813 IND submission in Q4 2026 and initial clinical data in H2 2027, which are the primary value-driving catalysts. The cash runway into Q1 2029 provides a long operational runway, reducing near-term financing risk. The stock will likely trade on pipeline execution and broader biotech sentiment rather than quarterly financial results.
Price Chart
Executive Summary
Century Therapeutics reported Q2 2026 financial results, with a net loss of $34.6M vs. $32.5M in Q2 2025, and cash of $197.2M providing runway into Q1 2029. The key catalyst is the progress of CNTY-813 (iPSC-derived islet therapy for T1D), with a pre-IND meeting completed and IND submission on track for Q4 2026, alongside initial clinical data expected in H2 2027. The company also remains on track to advance CNTY-308 into the clinic in 2026. The filing is neutral as it is a pre-revenue biotech with no new financial guidance, and the pipeline milestones, while positive, are expected and do not represent a material change in the company's outlook.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and investments were $197.2 million as of June 30, 2026, providing runway into Q1 2029.
- Completed pre-IND meeting with the FDA for CNTY-813; IND submission on track for Q4 2026.
- CNTY-308 remains on track to enter the clinic in 2026.
- Net loss was $34.6 million for Q2 2026, compared to a net loss of $32.5 million for Q2 2025.
- R&D expenses decreased to $19.6 million from $26.9 million year-over-year.
- G&A expenses decreased to $5.8 million from $7.8 million year-over-year.
Financial Impact
Net loss of $34.6M in Q2 2026, cash burn of ~$20M per quarter based on cash position change from Q1 2026 ($217M) to Q2 2026 ($197.2M).
Risk Factors
- Clinical trial failure or delay for CNTY-813 or CNTY-308.
- Dilution risk from future capital raises to fund operations beyond current cash runway.
- Competition from other cell therapy and islet replacement programs (e.g., Vertex's VX-880).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094533 |
| Document: tm2622911d1_ex99-2.htm | 0001104659-26-094533 |
| Document: tm2622911d1_8k.htm | 0001104659-26-094533 |
| Document: 0001104659-26-094533-index-headers.html | 0001104659-26-094533 |
| Document: 0001104659-26-094533-index.html | 0001104659-26-094533 |
| Document: 0001104659-26-094533.txt | 0001104659-26-094533 |
| 8-K Data (Synthetic) | 0001104659-26-094533 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.42 (−7.19%) |
Oct 2, 2026 24d ago | Press Release | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.42 (−7.19%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.89 $1.76 | ▼ −6.88% | ▼ −6.16% | $1.42 (−24.87%) |
Sep 10, 2026 6w ago | 3 | $1.94 $2.00 | ▲ +3.09% | ▲ +3.54% | $1.42 (−26.80%) |
Aug 12, 2026 10w ago | 8-K | $1.96 $1.93 | ▼ −1.53% | ▼ −2.23% | $1.42 (−27.55%) |
Aug 12, 2026 10w ago | Press Release | $1.96 $1.93 | ▲ +1.53% | ▲ +2.23% | $1.42 (+27.55%) |
Jun 16, 2026 18w ago | 8-K | $2.25 $2.29 | ▲ +1.78% | ▲ +1.00% | $1.42 (−36.89%) |
Jun 15, 2026 19w ago | Insider Cluster | $2.18 $2.25 | ▲ +3.21% | ▲ +4.46% | $1.42 (−34.86%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.42 (−33.02%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.42 (−33.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers